Moleculin Biotech, Inc. — Form 8-K Summary
Reporting date: October 30, 2026. This Form 8-K reports a clinical-development update under Item 7.01, Regulation FD Disclosure.
Business context and development update
Moleculin announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial. The trial evaluates Annamycin in combination with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML).
Financial performance and liquidity
This 8-K does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial results.
Outlook, risks, and notable items
The company says it remains on track to report comprehensive Part A data in the first quarter of 2027. The filing provides no trial results or further guidance. Clinical efficacy and safety outcomes remain to be evaluated; no additional risk or contingency details are provided in the filing text.
The Item 7.01 information, including the press release identified as Exhibit 99.1, is furnished and is not deemed filed under the Exchange Act unless specifically incorporated by reference in another filing. The press release itself is referenced but not included in the supplied text.
Important facts for investors to verify
- Whether the company reports comprehensive Part A data in Q1 2027 and what the results show.
- The trial’s efficacy, safety, and other material findings when disclosed.
- Any financial or liquidity updates in the company’s periodic filings; this 8-K contains none.